Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CENPE | Q02224 | 1/20 | 0.56 |
| ▸ | KIFC1 | Q9BW19 | 1/20 | 0.46 |
| ▸ | S1PR1 | P21453 | 2/20 | 0.44 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.39 |
| ▸ | SMPD1 | P17405 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.39 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13162513 | 0.94 | CENPE (0.55) | CENPEKIFC1S1PR1S1PR3KMT2A | |
| SCHEMBL2101902 | 0.91 | CENPE (0.51) | CENPEKIFC1S1PR1S1PR3KMT2A | |
| SCHEMBL2104964 | 0.90 | CENPE (0.53) | CENPEKIFC1S1PR1S1PR3KMT2A | |
| SCHEMBL2104733 | 0.90 | CENPE (0.56) | CENPEKMT2AMEN1KDM4EMAPT | |
| SCHEMBL2104606 | 0.88 | CENPE (0.48) | CENPEKIFC1S1PR1KMT2AMEN1 | |
| SCHEMBL2103273 | 0.88 | CENPE (0.50) | CENPEKMT2AMEN1CYP1A2CYP2C9 | |
| SCHEMBL14031509 | 0.87 | CENPE (0.50) | CENPEKIFC1S1PR1S1PR3KMT2A | |
| SCHEMBL2617484 | 0.85 | HPSE (0.46) | CENPEALDH1A1KDM4EMAPTLMNA | |
| SCHEMBL4721152 | 0.85 | CENPE (0.52) | CENPEKIFC1S1PR1S1PR3KMT2A | |
| SCHEMBL2107051 | 0.84 | CENPE (0.47) | CENPEMAPTHDAC8HDAC1HDAC6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100069453-A1 | Certain Chemical Entities, Compositions, and Methods | CYTOKINETICS, INC. | 2010-03-18 | — | — | US | claimed |
| EP-1951719-A2 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | Cytokinetics, Inc. (US) | 2008-08-06 | — | — | EP | claimed |
| US-20070149516-A1 | Certain chemical entities, compositions, and methods | CYTOKINETICS, INCORPORATED | 2007-06-28 | — | — | US | claimed |
| WO-2007056469-A2 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | CYTOKINETICS, INC. (US) | 2007-05-18 | — | — | WO | claimed |
| US-20060247289-A1 | Certain chemical entities, compositions, and methods | CYTOKINETICS, INCORPORATED | 2006-11-02 | — | — | US | claimed |
| US-8772507-B2 | Imidazole-benzamide anti-cancer agents | CYTOKINETICS, INC. (US) | 2014-07-08 | — | — | US | disclosed |
| US-8772507-B2 | Imidazole-benzamide anti-cancer agents | CYTOKINETICS, INC. (US) | 2014-07-08 | — | — | US | disclosed |
| US-20130096315-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS | QIAN XIANGPING (US) | 2013-04-18 | — | — | US | disclosed |
| US-20130096315-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS | QIAN XIANGPING (US) | 2013-04-18 | — | — | US | disclosed |
| US-20120283287-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | QIAN XIANGPING (US) | 2012-11-08 | — | — | US | disclosed |
| US-20120283287-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | QIAN XIANGPING (US) | 2012-11-08 | — | — | US | disclosed |
| US-8207340-B2 | Imidazopyridinyl benzamide mitotic kinesin inhibitors | CYTOKINETICS, INCORPORATED (US) | 2012-06-26 | — | — | US | disclosed |
| US-20080255182-A1 | Certain chemical entities, compositions, and methods | CYTOKINETICS, INC. | 2008-10-16 | — | — | US | disclosed |
| US-20080255182-A1 | Certain chemical entities, compositions, and methods | CYTOKINETICS, INC. | 2008-10-16 | — | — | US | disclosed |
| US-20080255182-A1 | Certain chemical entities, compositions, and methods | CYTOKINETICS, INC. | 2008-10-16 | — | — | US | disclosed |
| US-20070149516-A1 | Certain chemical entities, compositions, and methods | CYTOKINETICS, INCORPORATED | 2007-06-28 | — | — | US | disclosed |
| US-20070149516-A1 | Certain chemical entities, compositions, and methods | CYTOKINETICS, INCORPORATED | 2007-06-28 | — | — | US | disclosed |
| US-20070149516-A1 | Certain chemical entities, compositions, and methods | CYTOKINETICS, INCORPORATED | 2007-06-28 | — | — | US | disclosed |
| WO-2007056469-A2 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | CYTOKINETICS, INC. (US) | 2007-05-18 | — | — | WO | disclosed |
| US-20060247289-A1 | Certain chemical entities, compositions, and methods | CYTOKINETICS, INCORPORATED | 2006-11-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100069453-A1 | Certain Chemical Entities, Compositions, and Methods | KIF5B, KIF2C, PLK1 | CENPE 54/4885KIFC1 4/4885S1PR1 2943/4885 |
| US-20060247289-A1 | Certain chemical entities, compositions, and methods | KIF5B, KIF2C, PLK1 | CENPE 54/4885KIFC1 4/4885S1PR1 2943/4885 |
| US-20080255182-A1 | Certain chemical entities, compositions, and methods | KIF5B, KIF2C, PLK1 | CENPE 54/4885KIFC1 4/4885S1PR1 2943/4885 |
| US-20120283287-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | KIF5B, KIF2C, PLK1 | CENPE 54/4885KIFC1 4/4885S1PR1 2943/4885 |
| US-20130096315-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS | KIF5B, KIF2C, PLK1 | CENPE 50/4885KIFC1 5/4885S1PR1 2584/4885 |
| US-20070149516-A1 | Certain chemical entities, compositions, and methods | KIF5B, KIF2C, PLK1 | CENPE 54/4885KIFC1 4/4885S1PR1 2943/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.